Organovo Holdings Inc Share Price Nyse
Equities
US68620A1043
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 | 370K 29.13M | Sales 2025 * | 444K 34.96M | Capitalization | 11.73M 924M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 | 27.9 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 26.4 x |
P/E ratio 2024 |
-0.52
x | P/E ratio 2025 * |
-0.73
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.81% |
Managers | Title | Age | Since |
---|---|---|---|
Keith Murphy
CEO | Chief Executive Officer | 52 | 31/12/06 |
Thomas Hess
DFI | Director of Finance/CFO | 60 | 30/09/21 |
Steve Kunszabo
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Adam Stern
BRD | Director/Board Member | 60 | 31/01/12 |
Keith Murphy
CEO | Chief Executive Officer | 52 | 31/12/06 |
David Gobel
BRD | Director/Board Member | 71 | 14/09/20 |
1st Jan change | Capi. | |
---|---|---|
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |